Cargando…

Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria

Sodium–glucose co-transporter 2 inhibitors (SGLT2is) reduce albuminuria and hard renal outcomes (decline of renal function, renal replacement therapy and renal death) in patients with/without type 2 diabetes at high cardiovascular or renal risk. The question arises whether baseline albuminuria also...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delanaye, Pierre, Wissing, Karl Martin, Scheen, Andre J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	CKJ Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690058/ https://www.ncbi.nlm.nih.gov/pubmed/34950459 http://dx.doi.org/10.1093/ckj/sfab096

Ejemplares similares

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

New and old GFR equations: a European perspective
por: Delanaye, Pierre, et al.
Publicado: (2023)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

What is central to renal nutrition: protein or sodium intake?
por: Wang, Angela Yee-Moon, et al.
Publicado: (2023)

Risk-based versus GFR threshold criteria for nephrology referral in chronic kidney disease
por: Oliva-Damaso, Nestor, et al.
Publicado: (2022)

Late outcomes of renal denervation are more favourable than early ones: facts or fancies?
por: Persu, Alexandre, et al.
Publicado: (2023)

Citation classics: ranking of the top 100 most cited articles in nephrology
por: Montinaro, Vincenzo, et al.
Publicado: (2018)

The new Clinical Kidney Journal, 4 years later
por: Ortiz, Alberto, et al.
Publicado: (2019)

Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution
por: Kanbay, Mehmet, et al.
Publicado: (2022)

The renal patient seen by non-renal physicians: the kidney embedded in the ‘milieu intérieur’
por: Perez-Villa, Felix, et al.
Publicado: (2020)

Polypharmacy influences the renal composite outcome in patients treated with sodium‐glucose cotransporter 2 inhibitors
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art
por: Granata, Antonio, et al.
Publicado: (2022)

Oncogenic mechanisms in renal insufficiency
por: Volovat, Simona Ruxandra, et al.
Publicado: (2020)

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022)

A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
por: Hwang, You-Cheol, et al.
Publicado: (2019)

Immune checkpoint inhibitors and their interaction with proton pump inhibitors–related interstitial nephritis
por: Miao, Jing, et al.
Publicado: (2023)

The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
por: Kanbay, Mehmet, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Kidney transplantation and COVID-19 renal and patient prognosis
por: Toapanta, Néstor, et al.
Publicado: (2021)

The Latin American Dialysis and Renal Transplantation Registry: report 2019
por: Luxardo, Rosario, et al.
Publicado: (2021)

Anaplastic lymphoma kinase inhibitors and their effect on the kidney
por: Bonilla, Marco, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Bone mineral density and mortality in end-stage renal disease patients
por: Iseri, Ken, et al.
Publicado: (2020)

Potential hazards of recent trends in liberal iron use for renal anemia
por: Nakanishi, Takeshi, et al.
Publicado: (2020)

Management of acute renal replacement therapy in critically ill cirrhotic patients
por: Del Risco-Zevallos, Jimena, et al.
Publicado: (2022)

Challenges of defining renal response in ANCA-associated vasculitis: call to action?
por: Odler, Balazs, et al.
Publicado: (2023)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
por: Sarafidis, Pantelis, et al.
Publicado: (2023)

Effects of Sodium Glucose Cotransporter 2 Inhibitor on Renal Renin-Angiotensin-Aldsoterone System
por: Takeda, Yoshiyu, et al.
Publicado: (2021)

Renal threshold for glucose reabsorption predicts diabetes improvement by sodium‐glucose cotransporter 2 inhibitor therapy
por: Osaki, Aya, et al.
Publicado: (2016)

SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
por: Kalay, Zeynepgul, et al.
Publicado: (2022)

Are endourological procedures for nephrolithiasis treatment associated with renal injury? A review of potential mechanisms and novel diagnostic indexes
por: Mykoniatis, Ioannis, et al.
Publicado: (2020)

Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy
por: Shye, Michael, et al.
Publicado: (2020)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia
por: Somaili, Mohammed, et al.
Publicado: (2022)

Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review
por: Kitchlu, Abhijat, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ssgriv1fq3l354kkmol8q1tr15